Pfizer and BioNTech Initiate P-I Study of mRNA-Based Combination Vaccine for the Treatment of COVID-19 and Influenza
Shots:
- The first participant has been dosed in a P-I trial evaluating the safety, tolerability, and immunogenicity of a nucleoside modRNA-based combination vaccine in 180 healthy volunteers aged 18 through 64yrs. against COVID-19 and influenza across the US
- The single-dose vaccine is a combination of Pfizer’s quadrivalent modRNA-based influenza vaccine qIRV, currently in P-III clinical development & Omicron-adapted bivalent COVID-19 vaccine based on BioNTech’s mRNA platform technology
- The new development program builds on the companies’ success in developing the first approved and most widely used mRNA vaccine for COVID-19. Both companies will share the development costs
Ref: Pfizer | Image: Pfizer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
